Genomic-derived markers for early detection of calcineurin inhibitor immunosuppressant-mediated nephrotoxicity

Toxicol Sci. 2011 Nov;124(1):23-34. doi: 10.1093/toxsci/kfr217. Epub 2011 Aug 24.

Abstract

Calcineurin inhibitor (CI) therapy has been associated with chronic nephrotoxicity, which limits its long-term utility for suppression of allograft rejection. In order to understand the mechanisms of the toxicity, we analyzed gene expression changes that underlie the development of CI immunosuppressant-mediated nephrotoxicity in male Sprague-Dawley rats dosed daily with cyclosporine (CsA; 2.5 or 25 mg/kg/day), FK506 (0.6 or 6 mg/kg/day), or rapamycin (1 or 10 mg/kg/day) for 1, 7, 14, or 28 days. A significant increase in blood urea nitrogen was observed in animals treated with CsA (high) or FK506 (high) for 14 and 28 days. Histopathological examination revealed tubular basophilia and mineralization in animals given CsA (high) or FK506 (low and high). We identified a group of genes whose expression in rat kidney is correlated with CI-induced kidney injury. Among these genes are two genes, Slc12a3 and kidney-specific Wnk1 (KS-Wnk1), that are known to be involved in sodium transport in the distal nephrons and could potentially be involved in the mechanism of CI-induced nephrotoxicity. The downregulation of NCC (the Na-Cl cotransporter coded by Slc12a3) in rat kidney following CI treatment was confirmed by immunohistochemical staining, and the downregulation of KS-Wnk1 was confirmed by quantitative real-time-polymerase chain reaction (qRT-PCR). We hypothesize that decreased expression of Slc12a3 and KS-Wnk1 could alter the sodium chloride reabsorption in the distal tubules and contribute to the prolonged activation of the renin-angiotensin system, a demonstrated contributor to the development of CI-induced nephrotoxicity in both animal models and clinical settings. Therefore, if validated as biomarkers in humans, SLC12A3 and KS-WNK1 could potentially be useful in the early detection and reduction of CI-related nephrotoxicity in immunosuppressed transplant patients when monitoring the health of kidney xenographs in clinical practice.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Calcineurin Inhibitors*
  • Chronic Disease
  • Down-Regulation
  • Early Diagnosis
  • Genetic Markers
  • Graft Rejection / prevention & control
  • Immunohistochemistry
  • Immunosuppressive Agents / pharmacology
  • Immunosuppressive Agents / therapeutic use
  • Immunosuppressive Agents / toxicity*
  • Kidney / drug effects
  • Kidney / metabolism
  • Kidney / pathology
  • Kidney Diseases / chemically induced
  • Kidney Diseases / genetics*
  • Kidney Diseases / pathology
  • Kidney Diseases / physiopathology
  • Kidney Transplantation
  • Male
  • Minor Histocompatibility Antigens
  • Protein Serine-Threonine Kinases / genetics*
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Drug / genetics*
  • Renin-Angiotensin System / drug effects
  • Solute Carrier Family 12, Member 3
  • Symporters / genetics*
  • WNK Lysine-Deficient Protein Kinase 1

Substances

  • Calcineurin Inhibitors
  • Genetic Markers
  • Immunosuppressive Agents
  • Minor Histocompatibility Antigens
  • Receptors, Drug
  • Slc12a3 protein, rat
  • Solute Carrier Family 12, Member 3
  • Symporters
  • Protein Serine-Threonine Kinases
  • WNK Lysine-Deficient Protein Kinase 1
  • Wnk1 protein, rat